Ranuhardy Dody, Suzanna Evlina, Sari Resti M, Hadisantoso Dwi W, Andalucia Rizka, Abdillah Arif
Division of Hematology and Medical Oncology, Dharmais Hospital National Cancer Center, Jakarta, Indonesia.
Acta Med Indones. 2018 Apr;50(2):104-109.
the expression of CD30, CD15, CD50, and PAX5 are used to help in confirming diagnosis of HL and sALCL; however data on the proportion of these markers have not been available. The study was aimed to identify the proportion of CD30, CD15, CD50 and PAX5 expressions and characteristics of patients with HL and sALCL at Dharmais National Cancer Center Hospital between 2005 and 2015.
a retrospective observational study was conducted using data from medical records and histopathological results of HL and sALCL adult patients who sought treatment at the hospital between 2005 and 2015. Immunohistochemistry (IHC) examinations were performed and data on the proportion of positive CD30, CD15, CD50, and PAX5 expressions were analyzed descriptively.
a total of 45 patients were recruited in this study, with the majority (42 patients, 93.3%) were HL patients and only 6.7% were sALCL patients. The median age of HL patients was younger than sALCL patients; 35 (18-72 years old) versus 54 (49-61 years old). Moreover, the immunohistochemistry examination demonstrated that the positive CD15, CD30, CD50, and PAX5 expressions were found respectively in 37.5%, 88.9%, 31.2%, and 31.2% patients with HL; while in patients with sALCL, in spite of their small sample size, positive CD30, CD15, CD50 and PAX5 expressions were found in 100%; 66,7%; 50%; and 50%, respectively. Overall, CD15, CD50, and PAX5 positive expressions were found in 39.5%, 32.4%, and 32.4% patients who had HL and sALCL; while positive expression of CD30 was found in 89.5% of them.
present study shows that almost 90% patients have positive CD30 expression; while the positive expressions of CD15, CD50, and PAX5 are found in less than 40% patients. It indicates that CD30 is an important diagnostic marker for HL and sALCL and it may improve treatment strategy.
CD30、CD15、CD50和PAX5的表达用于辅助确诊霍奇金淋巴瘤（HL）和间变性大细胞淋巴瘤（sALCL）；然而，关于这些标志物比例的数据尚无可用资料。本研究旨在确定2005年至2015年期间在达玛伊斯国家癌症中心医院HL和sALCL患者中CD30、CD15、CD50和PAX5表达的比例及患者特征。
采用回顾性观察研究，使用2005年至2015年期间在该医院寻求治疗的HL和sALCL成年患者的病历数据和组织病理学结果。进行免疫组织化学（IHC）检查，并对CD30、CD15、CD50和PAX5阳性表达比例的数据进行描述性分析。
本研究共纳入45例患者，其中大多数（42例，93.3%）为HL患者，只有6.7%为sALCL患者。HL患者的中位年龄低于sALCL患者；分别为35岁（18 - 72岁）和54岁（49 - 61岁）。此外，免疫组织化学检查显示，HL患者中CD15、CD30、CD50和PAX5阳性表达分别见于37.5%、88.9%、31.2%和31.2%的患者；而在sALCL患者中，尽管样本量较小，CD30、CD15、CD50和PAX5阳性表达分别见于100%、66.7%、50%和50%的患者。总体而言，HL和sALCL患者中CD15、CD50和PAX5阳性表达分别见于39.5%、32.4%和32.4%的患者；而CD30阳性表达见于89.5%的患者。
本研究表明，近90%的患者CD30表达阳性；而CD15、CD50和PAX5阳性表达见于不到40%的患者。这表明CD30是HL和sALCL的重要诊断标志物，可能有助于改善治疗策略。
